{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:46:24Z","timestamp":1790811984069,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["onlinecjc.ca","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.cjca.2016.09.010","type":"journal-article","created":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T07:12:30Z","timestamp":1476861150000},"page":"350-357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["New Drugs for Atherosclerosis"],"prefix":"10.1016","volume":"33","author":[{"given":"Caroline S.","family":"Bruikman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Stoekenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2016.09.010_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.09.010_bib2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/eurheartj\/ehu107","article-title":"The ACC\/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC\/EAS guidelines for the management of dyslipidaemias 2011","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2016.09.010_bib3","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jacc.2015.10.077","article-title":"Reduction in total cardiovascular events with ezetimibe\/simvastatin post-acute coronary syndrome: The IMPROVE-IT trial","volume":"67","author":"Murphy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.09.010_bib4","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0140-6736(14)61009-6","article-title":"LDL cholesterol: controversies and future therapeutic directions","volume":"384","author":"Ridker","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.09.010_bib5","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-associated side effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2016.09.010_bib6","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.cjca.2016.09.010_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11883-014-0439-8","article-title":"Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs","volume":"16","author":"Abifadel","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.cjca.2016.09.010_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","article-title":"Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis","volume":"163","author":"Navarese","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2016.09.010_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.cjca.2016.09.010_bib10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.09.010_bib11","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.09.010_bib12","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.09.010_bib13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.09.010_bib14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","article-title":"Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease","volume":"316","author":"Kazi","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2016.09.010_bib15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","article-title":"Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia","volume":"105","author":"Akdim","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2016.09.010_bib16","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial","volume":"375","author":"Raal","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.09.010_bib17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40256-014-0077-0","article-title":"Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials","volume":"14","author":"Li","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cjca.2016.09.010_bib18","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial","volume":"33","author":"Visser","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2016.09.010_bib19","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","article-title":"Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease","volume":"126","author":"Stein","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2016.09.010_bib20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jacl.2014.12.006","article-title":"Efficacy and safety of mipomersen in treatment of dyslipidemia: a meta-analysis of randomized controlled trials","volume":"9","author":"Panta","year":"2015","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.09.010_bib21","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9149(03)00721-5","article-title":"Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol","volume":"92","author":"Bays","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2016.09.010_bib22","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3109\/07853890.2014.931100","article-title":"Microsomal transfer protein (MTP) inhibition\u2014a novel approach to the treatment of homozygous hypercholesterolemia","volume":"46","author":"Sirtori","year":"2014","journal-title":"Ann Med"},{"key":"10.1016\/j.cjca.2016.09.010_bib23","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1194\/jlr.M002915","article-title":"Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia","volume":"51","author":"Visser","year":"2010","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.cjca.2016.09.010_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.09.010_bib25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jacl.2015.11.011","article-title":"LOWER, a registry of lomitapide-treated patients with homozygous familial hypercholesterolemia: rationale and design","volume":"10","author":"Blom","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.09.010_bib26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/MJT.0000000000000063","article-title":"New and emerging LDL cholesterol-lowering drugs","volume":"22","author":"Kosmas","year":"2015","journal-title":"Am J Ther"},{"key":"10.1016\/j.cjca.2016.09.010_bib27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jacl.2015.12.025","article-title":"Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in patients with hypercholesterolemia with or without statin intolerance","volume":"10","author":"Thompson","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.cjca.2016.09.010_bib28","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/S0022-2275(20)39245-2","article-title":"Role of plasma lecithin:cholesterol acyltransferase in the metabolism of high density lipoproteins","volume":"7","author":"Glomset","year":"1966","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.cjca.2016.09.010_bib29","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.09.010_bib30","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.09.010_bib31","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients","volume":"349","author":"Keene","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2016.09.010_bib32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cmet.2016.01.005","article-title":"New therapeutic approaches to the treatment of dyslipidemia","volume":"23","author":"Rader","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.cjca.2016.09.010_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11886-016-0724-y","article-title":"CETP inhibition in CVD prevention: an actual appraisal","volume":"18","author":"Di Bartolo","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.cjca.2016.09.010_bib34","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.09.010_bib35","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ahj.2015.09.007","article-title":"Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: rationale and design of the ACCELERATE trial","volume":"170","author":"Nicholls","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2016.09.010_bib36","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(14)62115-2","article-title":"Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"385","author":"Kastelein","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.09.010_bib37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.amjcard.2013.08.041","article-title":"Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease","volume":"113","author":"Gotto","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2016.09.010_bib38","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","article-title":"Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"386","author":"Hovingh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.09.010_bib39","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant apoa-I Milano on coronary atherosclerosis in patients with acute coronary syndromes","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2016.09.010_bib40","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","article-title":"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial","volume":"35","author":"Tardif","year":"2014","journal-title":"Eur Heart J"},{"issue":"suppl 3","key":"10.1016\/j.cjca.2016.09.010_bib41","first-page":"A12156","article-title":"Greater regression of coronary atherosclerosis with the pre-beta high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden [abstract 12156]","volume":"132","author":"Kataoka","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2016.09.010_bib42","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.ahj.2015.01.008","article-title":"The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study","volume":"169","author":"Hovingh","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2016.09.010_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ahj.2016.06.017","article-title":"Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myo","volume":"180","author":"Gibson","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2016.09.010_bib44","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1089\/hum.2013.063","article-title":"From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world","volume":"24","author":"Kastelein","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.cjca.2016.09.010_bib45","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MOL.0b013e3283555a7e","article-title":"Gene therapy for lipoprotein lipase deficiency","volume":"23","author":"Gaudet","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.cjca.2016.09.010_bib46","first-page":"681","article-title":"Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency","volume":"11","author":"Burnett","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.cjca.2016.09.010_bib47","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1089\/hum.2015.158","article-title":"Long-term retrospective analysis of gene therapy with alipogene tiparvovec and its effect on lipoprotein lipase deficiency-induced pancreatitis","volume":"27","author":"Gaudet","year":"2016","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.cjca.2016.09.010_bib48","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2016.09.010_bib49","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/CIRCRESAHA.115.304008","article-title":"AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia","volume":"115","author":"Somanathan","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2016.09.010_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.cjca.2016.09.010_bib51","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","article-title":"Antisense oligonucleotide inhibition of apolipoprotein C-III Reduces plasma triglycerides in rodents, nonhuman primates, and humans","volume":"112","author":"Graham","year":"2013","journal-title":"Circ Res"},{"issue":"23","key":"10.1016\/j.cjca.2016.09.010_bib52","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.09.010_bib53","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2016.09.010_bib54","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1194\/jlr.R053066","article-title":"Current therapies for lowering lipoprotein(a)","volume":"57","author":"van Capelleveen","year":"2016","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.cjca.2016.09.010_bib55","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2016.09.010_bib56","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","article-title":"Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study","volume":"386","author":"Tsimikas","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2016.09.010_bib57","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X16310133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X16310133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T17:56:47Z","timestamp":1657475807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X16310133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0828282X16310133"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2016.09.010","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Drugs for Atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2016.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}